New Delhi, Jun 16 (PTI) Zydus Cadila, part of Cadila Healthcare group, on Tuesday said it has received final approval from the US health regulator to market its generic version of Deferasirox tablets used in treatment of chronic iron overload due to blood transfusions.

The approval by the US Food and Drug Administration (USFDA) for Deferasirox tablets is for multiple strengths of 90 mg, 180 mg and 360 mg, Cadila Healthcare said in a regulatory filing.

Also Read | Microsoft Partners With SAS to Make 'Azure' the Preferred Platform for SAS's Analytics Portfolio.

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least two years old.

It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old, the company said.

Also Read | WhatsApp Digital Payments Launched in Brazil to Make Money Transfer Easier.

"The drug will be manufactured at the group's manufacturing facility at special economic zone, Ahmedabad," it added.

The group now has 291 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in FY 2003-04.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)